PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Yuhang Chen

Department of Integrative Oncology, Fudan University, Shanghai, China.

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

MAY 19, 2026 · JOURNAL ARTICLE

UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway.

Cell Cycle

This is a mechanistic cell and tissue study demonstrating that UBE2C knockdown suppresses pancreatic cancer cell behavior through PI3K/Akt/mTOR pathway inhibition, with reversal by pathway activator SC79, but lacks clinical trial data, human efficacy endpoints, or effect sizes with confidence intervals.

PreliminaryNeoplasm Invasiveness Zhou Zhou Yuhang Chen

Reported

Pancreatic cancer incidence and m…approximately 496,000 new cases and 466,000…

5-year survival rate for resected…20%-30%

Recurrence rate for resected panc…70%-80%

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support